Medpace Holdings, Inc. (MEDP) Net Profit Margin: 17.19%
Is Medpace Holdings, Inc.’s net profit margin high or low?
Medpace Holdings, Inc.'s net profit margin of 17.19% is in line with its 5-year average of 16.74%, around the middle of its 5-year range (15.00%–19.17%).
As of Wednesday, June 17, 2026. 7.08% below its 12-month average of 18.50%.
MEDP Net Profit Margin Chart
MEDP Average Net Profit Margin Chart
MEDP Current vs Average Net Profit Margin Chart
MEDP Net Profit Margin Metrics
NET PROFIT MARGIN
17.19%
NET PROFIT MARGIN AVG TTM
18.50%
NET PROFIT MARGIN AVG 3Y
17.20%
NET PROFIT MARGIN AVG 5Y
16.74%
NET PROFIT MARGIN AVG 10Y
12.02%
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.08%
CURRENT VS 3Y AVG
-0.07%
CURRENT VS 5Y AVG
+2.70%
CURRENT VS 10Y AVG
+43.01%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 17.19% | 18.50% | 17.20% | 16.74% |
| Solventum Corporation (SOLV)vs › | $12.91B | 17.33% | 12.25% | 14.36% | 15.15% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 5.57% | 9.62% | 9.77% | 24.94% |
| DaVita Inc. (DVA)vs › | $13.52B | 5.65% | 6.39% | 5.83% | 6.41% |
| Align Technology, Inc. (ALGN)vs › | $12.43B | 10.50% | 10.36% | 10.48% | 22.21% |
| Revvity, Inc. (RVTY)vs › | $10.91B | 8.30% | 9.60% | 8.02% | 12.66% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -4.07% | -4.03% | -0.72% | 0.14% |
| Baxter International Inc. (BAX)vs › | $10.29B | -9.70% | -7.30% | -3.29% | 1.14% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 13.18% | 16.70% | 17.87% | 22.37% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.78B | -4.59% | -1.67% | 5.09% | 7.31% |
Margin Comparison
Operating Margin
21.0%
Net Profit Margin
17.2%
Medpace Holdings, Inc. Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Net Profit Margin FAQ
- What is the net profit margin for Medpace Holdings, Inc. (MEDP)?
- The net profit margin for MEDP stock is 17.19%.
- Is Medpace Holdings, Inc.'s net profit margin high or low?
- Medpace Holdings, Inc.'s net profit margin of 17.19% is in line with its 5-year average of 16.74%, around the middle of its 5-year range (15.00%–19.17%).
- What is the TTM average net profit margin for Medpace Holdings, Inc. (MEDP)?
- The TTM average net profit margin for MEDP stock is 18.50%.
- What is the 3Y average net profit margin for Medpace Holdings, Inc. (MEDP)?
- The 3Y average net profit margin for MEDP stock is 17.20%.
- What is the 5Y average net profit margin for Medpace Holdings, Inc. (MEDP)?
- The 5Y average net profit margin for MEDP stock is 16.74%.
- What is the 10Y average net profit margin for Medpace Holdings, Inc. (MEDP)?
- The 10Y average net profit margin for MEDP stock is 12.02%.
Medpace Holdings, Inc. Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 17.83% |
| 2024-12-31 | 19.17% |
| 2023-12-31 | 15.00% |
| 2022-12-31 | 16.81% |
| 2021-12-31 | 15.92% |
| 2020-12-31 | 15.70% |
| 2019-12-31 | 11.67% |
| 2018-12-31 | 10.39% |
| 2017-12-31 | 8.97% |
| 2016-12-31 | 3.18% |
| 2015-12-31 | -2.42% |
| 2014-12-31 | -5.37% |
| 2013-12-31 | 9.10% |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle